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To investigate whether there are differences between members of the Burkholderia cepacia
complex in their ability to invade human respiratory epithelial cells, 11 strains belonging
to genomovars I–V were studied in an antibiotic protection assay using the A549 cell line.
Strains belonging to genomovars II and III were more invasive than those of genomovars
I, IV and V. There was also intra-genomovar variation in invasiveness. No correlation
between invasiveness and other putative virulence factors of importance in B. cepacia
infection in individuals with cystic ﬁbrosis, cable pilus and B. cepacia epidemic strain
marker was identiﬁed.
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Pulmonary colonization in cystic ﬁbrosis (CF)
patients with Burkholderia cepacia may lead to
one of three clinical outcomes: persistent coloniza-
tion without deterioration, accelerated reduction
in lung function, or in about 20% of patients, rapid
deterioration with a fatal necrotizing pneumonia
sometimes accompanied by bacteremia known as
the ‘cepacia syndrome’ [1]. It is not known what
factors are responsible for these differences.
Although host factors are likely to be of impor-
tance, it is also possible that they may be due, at
least in part, to differences in the B. cepacia strains
infecting CF patients.
Each of the six genomovars which comprise the
B. cepacia complex have been recovered from CF
patients, however, strains of genomovars II (B.
multivorans) and III account for the majority of
CF isolates. The latter represent the majority of
epidemic strains of B. cepacia and are associated
with greater morbidity and mortality than any
other members of the B. cepacia complex [2,3].
However, the distribution of genomovars in the
CF patient community has not been systematically
determined and the pathogenic signiﬁcance of the
different genomovars is not known.
Virulence markers such as the cable (cbl) pilus
[4] and the B. cepacia epidemic strain marker
(BCESM) [5] occur almost exclusively in genomo-
var III. However, not all outbreak strains belong to
genomovar III. Moreover, the BCESM is also found
outside genomovar III [6]. Comparison of the nat-
ural history of colonization by genomovar II and
III strains has revealed striking differences and it
has been suggested that genomovar III colonized
patients are more likely to experience an adverse
clinical outcome [2]. This evidence suggests that
there are differences in the pathogenic potential of
strains belonging to different genomovars.
Despite the acknowledged signiﬁcance of B.
cepacia, comparatively little is known of the viru-
lence factors of importance in the natural history of
infection associated with the bacterium. There is,
however, convincing evidence to suggest that B.
cepacia can invade and survive within human cells
[7–9]. The aim of this study, therefore, was to
determine whether there are differences between
members of the B. cepacia complex in their ability to
invade respiratory epithelial cells.
The B. cepacia strains used, all from the BCCM/
LMG Bacteria Collection, University of Gent,
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Belgium, are shown in Table 1. Invasiveness was
determined in a ceftazidime–gentamicin protec-
tion assay, as described previously [8], by labora-
tory workers blinded to the identity of each isolate.
Brieﬂy, monolayers of A549 cells were prepared in
24-well tissue culture plates and were infected
with a suspension of stationary-phase (approxi-
mately 16 h) bacteria to yield a multiplicity of
infection of approximately 10 bacteria per A549
cell. Stationary-phase bacteria were used in pre-
ference to cells in the exponential phase, as inva-
siveness is greater under the former conditions
[10]. The numbers of bacteria added were deter-
mined by viable cell counts on Iso-Sensitest agar
(Unipath Ltd., Basingstoke, UK). Infected mono-
layers were then incubated at 37 8C in a humid
atmosphere containing 5%CO2 for 2 h, whereupon
they were washed thrice with sterile phosphate-
buffered saline. Low protein hybridoma medium
(LPHM, Gibco, Paisley, UK) containing 500mg/L
ceftazidime, and 160mg/L gentamicin was then
added to prevent further growth of extracellular
bacteria. This was taken as time-point zero (T0).
Numbers of intracellular bacteria [colony-forming
units (CFU)/mL] were determined by viable cell
counts of serial dilutions on Iso-Sensitest agar
following lysis of the pneumocytes with 0.3%
(v/v) Triton X-100 (Sigma, Poole, UK) at T0 and
T2 post-infection. Experiments were performed in
duplicate on three separate occasions. The number
of bacteria at T0 was assumed to represent the
number of internal bacteria plus the number of
extracellular bacteria (i.e. bacteria attached to the
monolayer), whereas numbers of bacteria at T2
post-infection were taken to represent only intra-
cellular bacteria. Assays for each strain were per-
formed in duplicate on three separate occasions
Results were analysed by either one-way or two-
way analyses of variance (ANOVA). Minimum sig-
niﬁcant differences (MSD) between means (n¼ 6)
were calculated by the T method [11].
All the strains of members of the B. cepacia
complex examined in this study were found to
invade and survive within respiratory epithelial
cells (Figure 1). However, differences in the degree
of invasiveness between genomovars were ob-
served. Strains belonging to genomovars II and
III were found to be more invasive in contrast to
the strains of genomovars I, IV and V. This, along
with the observation that most CF isolates belong
to genomovars II and III, and that genomovar III
isolates comprise the epidemic strains associated
with greater morbidity and mortality [2,3], implies
that CF patients colonized with genomovar II and
III isolates might possibly be at a greater risk of an
adverse clinical outcome following infection with
these genomovars.
Signiﬁcant differences in invasion between
strains within each of the genomovars II and III
were also found. The genomovar II CF isolate was
signiﬁcantly more invasive than the soil isolate,
although the latter was still more invasive than any
of the strains belonging to genomovars I, IV, or V.
In addition, it did not differ signiﬁcantly in inva-
siveness to strains LMG 12615 and LMG 14271 of
genomovar III. Therefore, environmental as well
as clinical strains of B. cepacia of genomovar II
might also present a potential risk to CF patients.
Table 1 Bacterial strains
Strain Genomovar Source
LMG 1222 I Onion
LMG 18821 I CF patient (Australia)
LMG 13010 II CF patient (Belgium)
LMG 17588 II Soil (USA)
LMG12615 III CF patient (UK)
LMG 16659 III CF patient (UK)
LMG 14271 III CF patient (Belgium)
LMG 7000 IV Blood culture (Sweden)
LMG 14291 IV CF patient (Belgium)
LMG 10929 V Rice rhizosphere (Vietnam)
LMG 16232 V CF patient (Sweden)
CF, cystic fibrosis.
Figure 1 Invasion of A549 respiratory epithelial cells by
members of the Burkholderia cepacia complex. Results are
expressed as mean of duplicate wells of three independent
experiments (n¼ 6) 95% confidence limits. Asterisks
indicate invasion significantly different from all other
strains (P< 0.05).
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Within genomovar III, the BCESMþ epidemic
strain LMG 16659 associated with a poor clinical
outcome was signiﬁcantly more invasive com-
pared with the other two genomovar III strains;
LMG 12615 (an epidemic strain of the ET12 lineage
possessing the cbl pilus and the BCESM marker);
and LMG 14271, a cbl– BCESM– strain, which were
not associated with a bad outcome. There was,
however, no signiﬁcant difference in invasiveness
between the latter. The degree of invasiveness
appears therefore to have no correlation with
the presence or absence of either the cbl pilus or
the BCESM marker.
The limitations of this study must be acknowl-
edged— only a very small number of examples of
each genomovar were studied. Nevertheless, evi-
dence from this preliminary study suggests that
there are differences in invasiveness between
members of the B. cepacia complex, with strains
belonging to genomovars II and III being more
invasive than strains belonging to genomovars I,
IV and V and that the invasive phenotype may be
associated with an adverse clinical outcome inde-
pendently of cbl pilus and BCESM. Further studies
are needed to determine the validity of the asso-
ciations between clinical outcome, genomovar and
invasiveness for respiratory epithelial cells, as this
may yield not only important prognostic informa-
tion, but may also permit relaxation of the strin-
gent isolation policies employed by CF centres
when patients are identiﬁed as being colonized
by B. cepacia.
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